Making a difference: Molecules, mechanisms and more

Gynecologic Oncology by Health Advance

Nov 17, 202538:54Science & Medicine

Editor’s Choice: A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer Editor’s Choice: Safety and efficacy of mirvetuximab sora...

Related Episodes

Continue listening to more episodes from Gynecologic Oncology.

ERAS 2026: Key Updates Every Gynecologic Oncologist Should Know

Jul 31, 2026 - 26:32

Editor's Choice: Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: 202...

Beyond the Binary: Unpacking Molecular Diversity in PMMR Endometrial Cancer

Jul 29, 2026 - 25:53

Editor's Choice: Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed...

Cologuard-like test for identification of endometrial cancer through vaginal sampling

May 13, 2026 - 25:41

Editor's Choice: Optimization of methylated DNA markers to rule out endometrial cancer in patients with a...

PARP Inhibitors in Ovarian Cancer: A Society of Gynecologic Oncology Podcast

May 8, 2026 - 19:50

Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian...

Home the Same Day? Testing the Limits in Ovarian Cancer Debulking Surgery

Apr 8, 2026 - 18:21

Editor's Choice: Same day discharge after minimally invasive interval debulking surgery in advanced stage...

Recognizing and Managing ADC-Associated Pulmonary Toxicities

Mar 16, 2026 - 29:40

Editor’s Choice: Interstitial lung disease in targeted therapies: A Society of Gynecologic Oncology clini...

In good SHAPE

Feb 1, 2026 - 23:45

Editor's Choice: Comparative outcomes of simple versus radical hysterectomy in patients with and wit...

ctDNA-Guided PARPi Therapy in Ovarian Cancer

Jan 1, 2026 - 25:21

Editor’s Choice: Circulating tumor DNA monitoring in ovarian cancer patients receiving PARPi maintenance...